IOVS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Levin, L. A.
Right arrow Articles by Johns, L. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Levin, L. A.
Right arrow Articles by Johns, L. K.

Investigative Ophthalmology & Visual Science, Vol 37, 2744-2749, Copyright © 1996 by Association for Research in Vision and Ophthalmology

ARTICLES AND REPORTS

Effect of lipid peroxidation inhibition on retinal ganglion cell death

LA Levin, JA Clark and LK Johns
Department of Ophthalmology and Visual Sciences, University of Wisconsin Medical School, Madison 53792, USA.

PURPOSE: To determine whether the lipid peroxidation inhibitor tirilazad mesylate can block the death of retinal ganglion cells induced by the inhibition of oxidative phosphorylation and glycolysis. METHODS: Rat retinal ganglion cells were labeled retrogradely with the fluorescent tracer DiI, and mixed cultures were prepared. Cell death was induced with chemical hypoxia, hypoglycemia, or glycolysis inhibition, and the effect on cell survival of tirilazad mesylate was assessed. RESULTS: Tirilazad mesylate enhanced relative ganglion cell survival after plating, with detectable effects at 200 nM and a maximal increase above diluent control of 148% +/- 2% at 20 microM. Relative survival at 24 hours in the presence of the complex IV inhibitor sodium cyanide (3 mM) was significantly greater when it was co-incubated with tirilazad mesylate than with diluent control (91.8% +/- 4.6% versus 39.3% +/- 7.1%; P = 0.008). Enhanced relative survival with tirilazad mesylate also was seen in cultures containing reduced glucose media. CONCLUSIONS: The lipid peroxidation blocker tirilazad mesylate inhibits retinal ganglion cell death in vitro. Because irreversible loss of retinal ganglion cells is the final common pathway in a variety of optic neuropathies, this or similar agents may be useful in animal models of optic neuropathies.


This article has been cited by other articles:


Home page
 IOVSHome page
C. J. Lieven, M. J. Hoegger, C. R. Schlieve, and L. A. Levin
Retinal ganglion cell axotomy induces an increase in intracellular superoxide anion.
Invest. Ophthalmol. Vis. Sci., April 1, 2006; 47(4): 1477 - 1485.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
K. I. Swanson, C. R. Schlieve, C. J. Lieven, and L. A. Levin
Neuroprotective Effect of Sulfhydryl Reduction in a Rat Optic Nerve Crush Model
Invest. Ophthalmol. Vis. Sci., October 1, 2005; 46(10): 3737 - 3741.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
E. Sugano, H. Tomita, S.-i. Ishiguro, T. Abe, and M. Tamai
Establishment of Effective Methods for Transducing Genes into Iris Pigment Epithelial Cells by Using Adeno-associated Virus Type 2
Invest. Ophthalmol. Vis. Sci., September 1, 2005; 46(9): 3341 - 3348.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
D. Gherghel, H. R. Griffiths, E. J. Hilton, I. A. Cunliffe, and S. L. Hosking
Systemic Reduction in Glutathione Levels Occurs in Patients with Primary Open-Angle Glaucoma
Invest. Ophthalmol. Vis. Sci., March 1, 2005; 46(3): 877 - 883.
[Abstract] [Full Text] [PDF]

Home page
 Am J EpidemiolHome page
J. H. Kang, L. R. Pasquale, W. Willett, B. Rosner, K. M. Egan, N. Faberowski, and S. E. Hankinson
Antioxidant Intake and Primary Open-Angle Glaucoma: A Prospective Study
Am. J. Epidemiol., August 15, 2003; 158(4): 337 - 346.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
P. Aoun, J. W. Simpkins, and N. Agarwal
Role of PPAR-{gamma} Ligands In Neuroprotection against Glutamate-Induced Cytotoxicity in Retinal Ganglion Cells
Invest. Ophthalmol. Vis. Sci., July 1, 2003; 44(7): 2999 - 3004.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
J. P. Vrabec, C. J. Lieven, and L. A. Levin
Cell-Type-Specific Opening of the Retinal Ganglion Cell Mitochondrial Permeability Transition Pore
Invest. Ophthalmol. Vis. Sci., June 1, 2003; 44(6): 2774 - 2782.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
K. Kashiwagi, Y. Iizuka, M. Araie, Y. Suzuki, and S. Tsukahara
Effects of Retinal Glial Cells on Isolated Rat Retinal Ganglion Cells
Invest. Ophthalmol. Vis. Sci., October 1, 2001; 42(11): 2686 - 2694.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
X. Luo, G. N. Lambrou, J. A. Sahel, and D. Hicks
Hypoglycemia Induces General Neuronal Death, Whereas Hypoxia and Glutamate Transport Blockade Lead to Selective Retinal Ganglion Cell Death In Vitro
Invest. Ophthalmol. Vis. Sci., October 1, 2001; 42(11): 2695 - 2705.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
K. Kortuem, L. K. Geiger, and L. A. Levin
Differential Susceptibility of Retinal Ganglion Cells to Reactive Oxygen Species
Invest. Ophthalmol. Vis. Sci., September 1, 2000; 41(10): 3176 - 3182.
[Abstract] [Full Text]

Home page
 Arch OphthalmolHome page
R. N. Weinreb and L. A. Levin
Is Neuroprotection a Viable Therapy for Glaucoma?
Arch Ophthalmol, November 1, 1999; 117(11): 1540 - 1544.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
L. K. Gordon and L. A. Levin
Visual Loss in Giant Cell Arteritis
JAMA, July 22, 1998; 280(4): 385 - 386.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1996 by the Association for Research in Vision and Ophthalmology